Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol
Top Cited Papers
Open Access
- 16 March 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 143 (11), 1109-1122
- https://doi.org/10.1161/circulationaha.120.049447
Abstract
Background: Recent international guidelines have lowered recommended target levels of low-density lipoprotein-cholesterol (LDL-C) for patients at very high risk for major adverse cardiovascular events (MACE). However, uncertainty persists whether additional benefit results from achieved LDL-C levels below conventional targets. Inferences from prior analyses are limited because patients who achieve lower versus higher LDL-C on lipid-lowering therapy differ in other characteristics prognostic for MACE and because few achieved very low LDL-C levels. To overcome these limitations, we performed a propensity score matching (PSM) analysis of the ODYSSEY OUTCOMES trial which compared alirocumab with placebo in 18,924 patients with recent acute coronary syndrome (ACS) receiving intensive or maximum-tolerated statin treatment. Methods: Patients on alirocumab were classified in prespecified strata of LDL-C achieved at 4 months of treatment: 50 mg/dL (n=2197). For each stratum, MACE (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina) after month 4 was compared in patients receiving placebo with similar baseline characteristics and adherence, using 1:1 PSM. Results: Across achieved LDL-C strata of the alirocumab group patients differed by baseline LDL-C, lipoprotein(a), use of intensive statin therapy, study medication adherence, and other demographic, medical history, biometric, and laboratory criteria. After PSM, characteristics were similar in corresponding patients of the alirocumab and placebo groups. Treatment hazard ratio (HR), 95% confidence interval (CI), and absolute risk reduction (ARR, number per 100 patient-years) for MACE were similar in those with achieved LDL-C 50 mg/dL had poorer adherence and derived less benefit (HR, 0.87; 95% CI, 0.73 to 1.04; ARR, 0.62). No safety concerns were associated with a limited period of LDL-C levels Conclusions: After accounting for differences in baseline characteristics and adherence, patients treated with alirocumab who achieved LDL-C levels Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier: NCT01663402This publication has 24 references indexed in Scilit:
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trialAmerican Heart Journal, 2014
- Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular EventsJournal of the American College of Cardiology, 2014
- Lipoprotein(a)-cholesterol: A significant component of serum cholesterolClinica Chimica Acta; International Journal of Clinical Chemistry, 2011
- Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin: The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)Journal of the American College of Cardiology, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Redefining Normal Low-Density Lipoprotein Cholesterol: A Strategy to Unseat Coronary Disease as the Nation's Leading KillerJournal of the American College of Cardiology, 2010
- Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normalJournal of the American College of Cardiology, 2004
- Propensity Score-Matching Methods for Nonexperimental Causal StudiesThe Review of Economics and Statistics, 2002
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- Decline in the concentration of low-density lipoprotein-cholesterol in human fetal plasma near termMetabolism, 1983